Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib with Bendamustine and Rituximab (ZBR) in Waldenstrom Macroglobulinemia
NCT05914662Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2023
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in Waldenstrom macroglobulinemia (WM), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Feb 2023; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT05914662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05914662.